|
Chronic fatigue in myelodysplastic syndromes: Looking beyond anemia |
Jul 2020 |
Critical reviews in hematology/oncology |
Myelodysplastic Syndromes (MDS) |
|
Activin Receptor II Ligand Traps: New Treatment Paradigm for Low-Risk MDS |
Jun 2019 |
Current Hematologic Malignancy Report |
Myelodysplastic Syndromes (MDS) |
|
Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents |
Apr 2023 |
Current Hematologic Malignancy Reports |
Myelodysplastic Syndromes (MDS) |
|
Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities |
Apr 2024 |
Current Hematologic Malignancy Reports |
Myelodysplastic Syndromes (MDS) |
|
Exploring treatment strategies for paroxysmal nocturnal hemoglobinuria: an overview of registered clinical trials |
May 2024 |
Current Medical Research and Opinion |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Germline mutations in MDS/AML predisposition disorders |
Mar 2021 |
Current opinion in hematology |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
Current Therapeutic Landscape in Lower Risk Myelodysplastic Syndromes |
May 2023 |
Current Treatment Options in Oncology |
Myelodysplastic Syndromes (MDS) |
|
Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes |
Jul 2023 |
European Journal of Haematology |
Myelodysplastic Syndromes (MDS) |
|
Beneficial effects of eculizumab regardless of prior transfusions or bone marrow disease: Results of the International PNH Registry |
Jul 2020 |
European Journal of Haematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Nationwide study of eculizumab in paroxysmal nocturnal hemoglobinuria: Evaluation of treatment indications and outcomes |
Jun 2023 |
European Journal of Haematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
